Share This Page
Suppliers and packagers for atnaa
✉ Email this page to a colleague
atnaa
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Us Army | ATNAA | atropine; pralidoxime chloride | INJECTABLE;INTRAMUSCULAR | 021175 | NDA | Meridian Medical Technologies, LLC | 11704-777-01 | 1 KIT in 1 CARTON (11704-777-01) * .7 mL in 1 SYRINGE, GLASS * 2 mL in 1 SYRINGE, GLASS | 2002-01-17 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ecutive summary No complete, accurate supplier map for the pharmaceutical drug “ATNAA” can be produced from available context because “ATNAA” is not uniquely identifiable as a single FDA-regulated drug name, INN/USAN, or Orange Book–listed product. A reliable supplier list requires a specific, unambiguous drug identity (active ingredient, dosage form, and brand or application record).
Drug “ATNAA” suppliers: Which companies provide APIs, intermediates, and finished dosage forms?
No determinate supplier answer is possible without an unambiguous identification of “ATNAA” as a specific marketed product or development-stage compound tied to a defined application (NDA/ANDA/BLA) and active ingredient.
What counts as an ATNAA “supplier” in practice?
A defensible supplier inventory typically separates:
- API manufacturers (drug substance)
- intermediate suppliers (key synthetic steps)
- finished dosage manufacturers (drug product)
- contract research and development providers supporting scale-up or formulation
- packaging and labeling vendors (where relevant)
Without the underlying drug identity, any company list would not be auditable or litigation-safe.
How do you find the real API and drug product suppliers for ATNAA?
A correct supplier sourcing workflow requires the drug’s regulatory record, since supply chains surface through:
- FDA “Drug Master File” holders (DMFs) and DMF-connected manufacturing sites
- Orange Book “Application Holder” and manufacturer fields
- Facility listings for sterile/non-sterile manufacture
- Investigator and sponsor disclosures in clinical registries
- Procurement disclosures in settlements and consent decrees (where public)
No supplier endpoints can be mapped to “ATNAA” without a specific drug record.
What is the Orange Book status of ATNAA, and does it reveal generic or branded manufacturers?
Orange Book status requires a specific FDA product identifier. Without that, there is no way to determine:
- listed drug (RLD) identity
- application number
- patent/exclusivity regime
- dosage form and strength matches used for supplier inference
Which companies might supply ATNAA if it is an OTC or compounding designation?
If “ATNAA” refers to a trade name used outside the Orange Book (or a compounding descriptor), it can be sourced under different commercial names and may not correspond to an FDA-listed RLD. In that scenario, supplier identification depends on the labeler of record and the actual API.
What generic entry risks exist for ATNAA based on supplier and patent signals?
Generic entry risk analysis depends on:
- whether there is an approved ANDA
- patent listings and exclusivity periods
- whether applicants rely on different polymorphs, salts, or formulations that change the supplier set
No patent and regulatory record can be linked to “ATNAA” as provided.
How does ATNAA formulation type change the supplier landscape (oral solids vs injectables)?
Supplier categories shift materially with dosage form:
- Sterile injectables rely on aseptic fill-finish networks with validated cleanroom operations and high regulatory scrutiny.
- Oral solids depend on crystallization, particle size distribution, and blending/granulation capabilities.
- Controlled-release products add polymer and coating supply constraints.
“ATNAA” is not enough to map to a dosage form and manufacturing template.
Can you compare ATNAA suppliers against competitors in the same therapeutic class?
A class comparison requires the therapeutic target and mechanism or at least the active ingredient. “ATNAA” does not provide that.
Key takeaways
- “ATNAA” is not uniquely identifiable as a specific FDA-regulated drug product from the information provided.
- Without an unambiguous drug identity (active ingredient + dosage form + brand/application record), supplier lists would be non-auditable.
FAQs
-
What data field uniquely identifies the correct FDA product record for supplier lookups?
Application number (NDA/ANDA/BLA) tied to the listed drug (RLD) name and strength/dosage form. -
Where do API suppliers typically appear in public sources?
FDA DMF listings and Orange Book manufacturing/application holder data. -
How do sterile dosage forms change supplier selection?
They shift toward aseptic fill-finish facilities and require validated sterility assurance systems and regulatory inspection history. -
Do supplier names differ between drug substance and drug product?
Yes. Companies often contract separately for API and for finished dosage manufacturing. -
What is the fastest way to confirm a supplier for a specific drug strength/form?
Cross-check the exact listed drug entry in the Orange Book against the associated application holder and manufacturing site fields.
References (APA)
No sources can be cited because “ATNAA” cannot be tied to a specific drug record from the provided prompt.
More… ↓
